National politics, state advocacy issues, and innovative topics in urologic care came together as urologists from every practice setting and at varied points in their careers gathered in Washington for the AACU 2019 annual meeting.
Experts take a deep dive into the latest advancement, exploring groundbreaking clinical trial data, real-world evidence of newly approved therapies, and ongoing research shaping the…
Already Registered? Login here. REGISTER NOW Already registered?
Data from the SCIMITAR trial showed that SBRT appeared safe and demonstrated comparable PROs compared with CFRT.
An expert walks through specific actions that urologists and their teams can take before, during, and after the procedure.
Nearly 60% of patients taking vibegron remained on treatment at 1 year.
“The use of telemedicine is heavily dependent on supportive legislature,” write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.
Yōni.Fit bladder support was granted FDA 510(k) clearance in May 2024.
ACOU085 will be administered in 1 ear, with a matching placebo injection in the respective contralateral middle ear.
The freedom from re-intervention rate was 71%.
Use of focal therapy was shown to prolong the duration of active surveillance.
